**Robust H2 2026 IPO activity and a crowded pipeline are the dominant drivers of trader sentiment on Polymarket’s “IPOs before 2027?” contracts.** U.S. equity issuance surged in the first half, with 192 IPOs (including SPACs) raising $153 billion, led by SpaceX’s record June debut; however, Q3 volume moderated amid AI-spending concerns, 19-year-high Treasury yields, and resumed rate-hike expectations. Recent pricings—such as ADARx Pharmaceuticals on September 24 and multiple smaller deals—plus active S-1 filings from Oura, Accelevation, and others underscore continued access for mid-sized issuers. Market-implied odds reflect company-specific timelines: Anthropic remains the clearest near-term candidate for a late-2026 listing, while OpenAI and several peers face greater 2027 slippage risk tied to valuation targets, regulatory reviews, and macro volatility. Key upcoming catalysts include FOMC decisions, fourth-quarter earnings, and stabilization in growth-stock performance that could either accelerate or defer filings.